Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icotinib - Zhejiang Betta Pharma

Next Previous
Drug Profile

Icotinib - Zhejiang Betta Pharma

Alternative Names: BPI-2009; BPI-2009C; BPI-2009H; Conmana; Icotinib hydrochloride

Latest Information Update: 22 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beta Pharma
  • Developer Beta Pharma; Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
  • Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Brain metastases; Lung cancer; Nasopharyngeal cancer; Neurofibromatosis 2; Oesophageal cancer; Psoriasis
  • No development reported Pancreatic cancer

Most Recent Events

  • 08 Apr 2022 Interim efficacy data from a phase II ICAPE trial in non-small-cell lung cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 07 Jan 2022 Registered for Non-small cell lung cancer (Adjuvant therapy) in China (PO) (Betta Pharmaceuticals pipeline,
  • 01 Oct 2021 Zhejiang Betta Pharma completes a phase II trial in Non-small cell lung cancer (Adjuvant therapy) in China (PO) (NCT02044328)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top